Cirrhosis Clinical Trial
Official title:
Effect of Yogurt Supplementation on Psychometric Test Performance in Cirrhotic Patients With Minimal Hepatic Encephalopathy. A Prospective Pilot Trial.
Verified date | October 2007 |
Source | Medical College of Wisconsin |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to determine whether a special yogurt can improve performance on certain tests of intelligence and decrease liver inflammation in patients with cirrhosis.
Status | Completed |
Enrollment | 30 |
Est. completion date | April 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 24 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Cirrhosis diagnosed on clinical grounds (within 3 months of enrollment) - MHE diagnosed by abnormalities in a psychometric battery (NCT-A,BDT,DST and ICT) Exclusion criteria: - Current or recent (< 6 month) use of alcohol - Co-existing cause of liver dysfunction - Use of antibiotics within last 6 weeks - Infection or gastrointestinal hemorrhage within the last 6 weeks - Hepatocellular carcinoma - Psychoactive drug use, including interferon concurrently |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | GCRC Medical College of Wisconsin | Milwaukee | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
Medical College of Wisconsin | National Center for Research Resources (NCRR) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reversal of minimal hepatic encephalopathy | |||
Secondary | Decrease in AST/ALT |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01884415 -
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05014594 -
Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
|
Phase 2 | |
Not yet recruiting |
NCT03631147 -
The Effect of Rifaximin on Portal Vein Thrombosis
|
N/A | |
Completed |
NCT04939350 -
Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
|
||
Completed |
NCT02528760 -
To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis
|
N/A | |
Recruiting |
NCT05484206 -
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
|
Phase 1 | |
Not yet recruiting |
NCT05538546 -
Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients
|
||
Not yet recruiting |
NCT04053231 -
Hepatocarcinoma Recurrence on the Liver Study - Part2
|
||
Recruiting |
NCT02983968 -
Use of the French Healthcare Insurance Database
|
||
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT02596880 -
Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics
|
Phase 3 | |
Completed |
NCT02247414 -
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
|
Phase 4 | |
Withdrawn |
NCT01956864 -
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
|
Phase 1 | |
Completed |
NCT02016196 -
Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS
|
Phase 3 | |
Completed |
NCT02113631 -
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
|
N/A | |
Completed |
NCT01447537 -
Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis
|
N/A | |
Completed |
NCT01362855 -
Advance Care Planning Evaluation in Hospitalized Elderly Patients
|
||
Active, not recruiting |
NCT01205074 -
¹³C-Methacetin Breath Test (MBT) Methodology Study
|
Phase 2/Phase 3 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01231828 -
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.
|
N/A |